Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorCellution Biologics

About this trial

The purpose of this study is to determine how well our dHPT (Dehydrated Human Placental Tissue) Product and Standard of Care work when compared to Standard of Care alone in achieving complete closure of venous leg ulcers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 years of age or older.

Hemoglobin A1c (HbA1c) level is <12% (108 mmol/mol).

Target ulcer with a surface area of between 1.0 cm 2 and 25.0 cm 2 measured post debridement at randomization.

Target ulcer must have been present for a minimum of 4 weeks with standard of care prior to the initial screening visit.

Disqualifiers

The participant must agree to attend the weekly study visits required by the protocol.

The participant must be willing and able to participate in the informed consent process

Known life expectancy of <6 months.

Target ulcer is infected or there is cellulitis in the surrounding skin.

Trial design

Design model

Crossover

Treatments tested in this trial

  • Amnion-Intermediate-Chorion

    Other intervention

    Dehydrated human placental multilayer allograft derived from donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.

  • Standard of Care (SOC)

    Procedure/Surgery

    Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Standard of CareActive comparator 1 intervention
Group B: AIC and Standard of CareExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Percentage of Venous Leg Ulcers with Complete Wound Closure

The percentage of VLU target ulcers achieving complete wound closure. Closure is defined as 100% re-epithelialization of the ulcer surface without detectable exudate.

Time frame
1-10 weeks

Secondary outcomes

1

Time to Complete Closure for Ulcer

Time to closure will be determined for the treatment group and compared to Standard of Care. Closure is defined by 100% re-epithelialization of the ulcer surface without detectable exudate.

Time frame
1-10 weeks
2

Percentage of Wound Area Change for Target Ulcer

Percentage wound area changes from week 1 to week 10 will be calculated weekly from measurements with digital photographic images and physical examination.

Time frame
1-10 weeks
3

Incidents of Adverse Events

Changes in quality of life using both the Wound Quality of Life (wQOL) and Forgotten Wound Score (FWS) questionnaires that measure the health-related quality of life (HRQoL) of patients with chronic wounds. wQOL questionnaire is scored using a 5-point Likert scale, where 0 means "not at all" and 4 means "very much". Higher scores indicate greater impairment of quality of life. Higher the score indicates lower quality of life. FWS questionnaire measures 12 activities scored 0-4. Responses are summed and divided by the number of completed items. The mean value is then multiplied by 25 to obtain the total score of 0-100. Higher the score indicates lower quality of life.

Time frame
1-10 weeks

Other outcomes

1

Changes in Pain Associated with the Target Ulcer

Change in pain in the target ulcer assessed using the Visual Analog Scale (VAS) from week 1 to week 10. VAS is a tool that uses a 0-10 (no o extreme pain) point scale to measure pain intensity.

Time frame
1-10 weeks

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: